PL447022A1 - Kompozycja farmaceutyczna do zastosowania do leczenia i regeneracji układu ruchu, kompozycja farmaceutyczna oraz sposób leczenia ją wykorzystujący - Google Patents

Kompozycja farmaceutyczna do zastosowania do leczenia i regeneracji układu ruchu, kompozycja farmaceutyczna oraz sposób leczenia ją wykorzystujący

Info

Publication number
PL447022A1
PL447022A1 PL447022A PL44702223A PL447022A1 PL 447022 A1 PL447022 A1 PL 447022A1 PL 447022 A PL447022 A PL 447022A PL 44702223 A PL44702223 A PL 44702223A PL 447022 A1 PL447022 A1 PL 447022A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
treatment
composition
triamcinolone
regeneration
Prior art date
Application number
PL447022A
Other languages
English (en)
Inventor
Cezary WASILCZYK
Original Assignee
Wasilczyk Cezary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wasilczyk Cezary filed Critical Wasilczyk Cezary
Priority to PL447022A priority Critical patent/PL447022A1/pl
Priority to PCT/PL2024/050097 priority patent/WO2025122019A1/en
Publication of PL447022A1 publication Critical patent/PL447022A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zgłoszenie dotyczy kompozycji farmaceutycznej, sposobu leczenia ją wykorzystującego oraz kompozycji farmaceutycznej do zastosowania do leczenia chorób układu ruchu, która jako czynnik aktywny zawiera autologiczne osocze bogatopłytkowe; lokalny anestetyk wybrany z lignokainy, ropiwakainy, bupiwakainy, benzokainę, chloroprokainy; związek przeciwobrzękowy wybrany z betametazonu, triamcynolonu, metyloprednizolonu, triamcynolonu, octanmetyloprednizolonu; kwas hialuronowy; somatortopinę i strofantynę, przy czym kompozycja farmaceutyczna przeznaczona jest do podawania w skutecznej dawce do leczonego miejsca docelowego układu ruchu osobnika, którym jest ssak, korzystniej człowiek.
PL447022A 2023-12-07 2023-12-07 Kompozycja farmaceutyczna do zastosowania do leczenia i regeneracji układu ruchu, kompozycja farmaceutyczna oraz sposób leczenia ją wykorzystujący PL447022A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL447022A PL447022A1 (pl) 2023-12-07 2023-12-07 Kompozycja farmaceutyczna do zastosowania do leczenia i regeneracji układu ruchu, kompozycja farmaceutyczna oraz sposób leczenia ją wykorzystujący
PCT/PL2024/050097 WO2025122019A1 (en) 2023-12-07 2024-12-05 Pharmaceutical composition for use in the treatment and regeneration of the musculoskeletal system, the pharmaceutical composition and the method of treatment with use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447022A PL447022A1 (pl) 2023-12-07 2023-12-07 Kompozycja farmaceutyczna do zastosowania do leczenia i regeneracji układu ruchu, kompozycja farmaceutyczna oraz sposób leczenia ją wykorzystujący

Publications (1)

Publication Number Publication Date
PL447022A1 true PL447022A1 (pl) 2025-06-09

Family

ID=95937368

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447022A PL447022A1 (pl) 2023-12-07 2023-12-07 Kompozycja farmaceutyczna do zastosowania do leczenia i regeneracji układu ruchu, kompozycja farmaceutyczna oraz sposób leczenia ją wykorzystujący

Country Status (2)

Country Link
PL (1) PL447022A1 (pl)
WO (1) WO2025122019A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151281A1 (en) * 2009-06-23 2010-12-29 Spinal Restoration, Inc. Methods and kits for treating joints and soft tissues
WO2014052640A1 (en) * 2012-09-28 2014-04-03 Ronald Plante Paul Novel ampk agonist compositions and methods of use
PL2628484T3 (pl) * 2012-02-17 2016-10-31 Bogatopłytkowe kompozycje osocza
PL426950A1 (pl) * 2018-09-07 2020-03-09 Wasilczyk Cezary Kompozycja farmaceutyczna i zestaw kompozycji, urządzenie do podawania zestawu kompozycji farmaceutycznych, sposób podania zestawu kompozycji oraz zastosowanie w regeneracji układu ruchu

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023270497A1 (en) * 2022-05-18 2024-12-05 Novartis Ag Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151281A1 (en) * 2009-06-23 2010-12-29 Spinal Restoration, Inc. Methods and kits for treating joints and soft tissues
PL2628484T3 (pl) * 2012-02-17 2016-10-31 Bogatopłytkowe kompozycje osocza
WO2014052640A1 (en) * 2012-09-28 2014-04-03 Ronald Plante Paul Novel ampk agonist compositions and methods of use
PL426950A1 (pl) * 2018-09-07 2020-03-09 Wasilczyk Cezary Kompozycja farmaceutyczna i zestaw kompozycji, urządzenie do podawania zestawu kompozycji farmaceutycznych, sposób podania zestawu kompozycji oraz zastosowanie w regeneracji układu ruchu

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN J COLE ET AL., "HYALURONIC ACID VERSUS PLATELET-RICH PLASMA: A PROSPECTIVE, DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL COMPARING CLINICAL OUTCOMES AND EFFECTS ON INTRA-ARTICULAR BIOLOGY FOR THE TREATMENT OF KNEE OSTEOARTHRITIS", AM J SPORTS MED. 2017 FEB;45(2):339-34 *

Also Published As

Publication number Publication date
WO2025122019A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
Degli Agosti et al. Effectiveness of a Short‐Term Treatment of Oxygen‐Ozone Therapy into Healing in a Posttraumatic Wound
Smith et al. Drug treatment of varicose veins, venous edema, and ulcers
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
Giuggioli et al. Procedural pain management in the treatment of scleroderma digital ulcers
EP3716996A1 (en) Wound debridement composition and method for treating wounds
CL2024001530A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
JP2019506397A (ja) モートン神経腫疼痛の治療のためのカプサイシン連続投薬方法
Fleischli et al. Use of postoperative steroids to reduce pain and inflammation
Rodrigues et al. Protective effects of mesenchymal stromal cell-derived secretome on dermonecrosis induced in rabbits by Loxosceles intermedia spider venom
GB2493914A (en) Flurbiprofen and related compounds for the treatment of skin diseases
US20150283189A1 (en) Medicament for treating muscle and skeletal diseases
EP4525870A4 (en) METHODS FOR TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND FOR REDUCING THE LIVER TOXICITY OF OTHER MEDICINES ADMINISTERED TO A PATIENT
MX2023013514A (es) Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
MX2023005663A (es) Tratamientos respiratorios.
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
PH12022553441A1 (en) Compositions and methods for treating obsessive-compulsive disorder
Shulman Heparin and atherosclerosis: an investigative report on the treatment of atherosclerosis
JP2022508512A5 (pl)
Mateshuk-Vatseba et al. The influence of an opioid on the course of reparative processes
Batifol et al. Treatment of keloid scars by botulinum toxin
Srinivasulu et al. Comparison of Submucosal Injection of Dexamethasone and Triamcinolone Acetonide for Control of Postoperative Pain after Impacted Mandibular Third Molar Surgery-A Prospective Randomized Controlled Trial
JP2024166033A (ja) 脱毛症の長期治療